Literature DB >> 18677644

Fulminant tumefactive multiple sclerosis: therapeutic implications of histopathology.

Michael R Haupts, Sebastian K Schimrigk, Nils Brune, Andrew Chan, Guido Ahle, Kerstin Hellwig, Fatima B König, Uwe Schlegel, Wolfgang Brück, Ralf Gold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18677644     DOI： 10.1007/s00415-008-0883-x

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  Relapsing-remitting tumefactive multiple sclerosis.

Authors:  Stephen M Selkirk; Jiong Shi
Journal:  Mult Scler       Date:  2005-12       Impact factor: 6.312

2.  Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease.

Authors:  Andrew Chan; De-Hyung Lee; Ralf Linker; Alexander Mohr; Klaus V Toyka; Ralf Gold
Journal:  J Neurol       Date:  2007-08-27       Impact factor: 4.849

3.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

4.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

Authors:  Mark Keegan; Fatima König; Robyn McClelland; Wolfgang Brück; Yazmín Morales; Andreas Bitsch; Hillel Panitch; Hans Lassmann; Brian Weinshenker; Moses Rodriguez; Joseph Parisi; Claudia F Lucchinetti
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

5.  Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Authors:  Olaf Stüve; Sabine Cepok; Birte Elias; Andreas Saleh; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Journal:  Arch Neurol       Date:  2005-10

6.  An open label study of the effects of rituximab in neuromyelitis optica.

Authors:  B A C Cree; S Lamb; K Morgan; A Chen; E Waubant; C Genain
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

Review 7.  Differentiation of multiple sclerosis subtypes: implications for treatment.

Authors:  Andreas Bitsch; Wolfgang Brück
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422
  8 in total
  6 in total

1.  Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Authors:  A Siri; Clarisse Carra-Dalliere; X Ayrignac; J Pelletier; B Audoin; S Pittion-Vouyovitch; M Debouverie; C Lionnet; F Viala; D Sablot; D Brassat; J-C Ouallet; A Ruet; B Brochet; L Taillandier; L Bauchet; N Derache; G Defer; P Cabre; J de Seze; C Lebrun Frenay; M Cohen; P Labauge
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

Review 2.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

3.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

Review 4.  Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.

Authors:  Aigli G Vakrakou; Maria-Evgenia Brinia; Ioanna Svolaki; Theodore Argyrakos; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

5.  Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis.

Authors:  Katja Akgün; Imke Metz; Hagen H Kitzler; Wolfgang Brück; Tjalf Ziemssen
Journal:  Ther Adv Neurol Disord       Date:  2018-03-08       Impact factor: 6.570

6.  Transtentorial herniation from tumefactive multiple sclerosis mimicking primary brain tumor.

Authors:  Kunal Vakharia; Haris Kamal; Gursant S Atwal; James L Budny
Journal:  Surg Neurol Int       Date:  2018-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.